Clinical trials: ifosfamide
Non-metastatic Soft-tissue Sarcoma, Resectable
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles…
- Trial name
- CIRSARC (NCT03805022)
- Testing
- Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
- Where
- 10 sites in France
- Volunteers
- 351 people
- Sponsor
- Institut Bergonié
Classical Hodgkin Lymphoma
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
This is an open-label, multicenter, randomized, phase3 trial to evaluate the efficacy of Camrelizumab in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT04342936
- Testing
- Camrelizumab, Investigator's choice of Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteosarcoma
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
The goal of this clinical research study is to learn if giving certain combinations of chemotherapy drugs before and after surgery, mostly in the outpatient clinic instead of in the hospital, can result in fewer hospital stays…
- Trial name
- NCT00673179
- Testing
- Doxorubicin, Cisplatin, Methotrexate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
- Trial name
- NCT04881240
- Testing
- CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Jude Children's Research Hospital
Peripheral T Cell Lymphoma
Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.
- Trial name
- NCT02856997
- Testing
- Chidamide with ICE regimen
- Volunteers
- 35 people
- Sponsor
- Yuankai Shi
Lymphoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002982
- Testing
- filgrastim, carboplatin, carmustine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors, Lymphoma
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
- Trial name
- NCT04570423
- Testing
- Eflapegrastim, Chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Effect of Drug, Drug
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Conditions
- Effect of Drug, Drug, Toxicity
- Trial name
- OAIE (NCT05277480)
- Testing
- Apatinib+IE, IE
- Where
- 5 sites in China
- Volunteers
- 81 people
- Sponsor
- Peking University People's Hospital
Extranodal NK/T-cell Lymphoma, Nasal Type
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.
- Trial name
- NCT01667302
- Testing
- Radiotherapy followed by chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Breast Cancer
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004172
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Northwestern University
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.
- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01026220
- Testing
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate
- Where
- 177 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
High-risk Neuroblastoma, Neuroblastoma
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
- Conditions
- High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
- Trial name
- NCT06528496
- Testing
- DANYELZA, Sargramostim, Cytoxan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy of concomitant chemoradiation followed by MIDLE chemotherapy for stage I/II extranodal NK/T cell lymphoma.
- Trial name
- NCT01238159
- Testing
- CCRT+MIDLE chemotherapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Central Nervous System Lymphoma
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
- Trial name
- NCT01458730
- Testing
- Immunochemotherapy
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Aarhus
Soft Tissue Sarcoma, Bone Sarcoma
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT…
- Trial name
- ImmunoSarc (NCT03277924)
- Testing
- Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin
- Where
- 13 sites in Italy, Spain and 1 more
- Volunteers
- 197 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
All patients are treated according to the same therapy regimen. Therapy duration (number of cycles) and radiotherapy vary according to age group, stage and response.
- Trial name
- NCT00797810
- Testing
- Rituximab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Bologna
OSTEOSARCOMA
Phase II Trial for the Treatment of Relapsed Osteosarcoma
Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma
- Trial name
- OsteoREC2015 (NCT02718482)
- Testing
- Gemcitabine and Docetaxel, Ifosfamide
- Where
- 10 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Italian Sarcoma Group
B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to…
- Trial name
- OLYMPIA-4 (NCT06230224)
- Testing
- Odronextamab, Ifosfamide, Carboplatin
- Where
- 81 sites in Argentina, Australia and 12 more
- Volunteers
- 216 people
- Sponsor
- Regeneron Pharmaceuticals
Gray Zone Lymphoma, Relapse/Recurrence
A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma
There are no standard chemotherapy regimens for relapse/refractory gray area lymphoma. The programmed cell death ligand 1 (PD-L1) encoding gene is located in 9p24.1, so it is speculated that the programmed cell death pathway…
- Conditions
- Gray Zone Lymphoma, Relapse/Recurrence, Chemotherapy Effect
- Trial name
- NCT04860674
- Testing
- PD-1 inhibitor +ICE
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital